Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Geron Corporation ($GERN) announced that the second internal data reviews of Imerge and Imbark have been completed by the Janssen Research & Development, LLC. These clinical trials are being done for the telomerase inhibitor imetelstat in lower risk myelodysplastic syndromes (MDS) and relapsed or refractory myelofibrosis (MF), respectively.
The review showed that for IMerge, the benefit/risk profile of imetelstat in the treated patients supports continued development in MDS. For IMbark, the current results suggest clinical benefit and a potential overall survival benefit associated with imetelstat treatment in MF. During the next year, Geron expects Janssen to evaluate maturing efficacy and safety data from the trial, including an assessment of overall survival.

Aurinia Pharmaceuticals Inc. ($AUPH) stock jumped in its previous trading session as the company reported that it plans to conduct only one Phase 3 clinical trial for supporting marketing applications in the U.S., EU and Japan seeking approval of voclosporin to treat lupus nephritis. The usual practice is to carry out two identical studies. The company also conducted discussions with regulators and concluded that data from the Phase 3 study, called AURORA, and the recently completed Phase 2b study, AURA-LV, should be sufficient to support the filings in all three jurisdictions.
The company stock has jumped over 235 percent this year so far while its 12 months gain stands at 147 percent.

 
BioTelemetry ($BEAT) announced its plan to file a tender offers for acquiring all the outstanding shareholders of LifeWatch AG. The shareholders will be entitled to receive either CHF10.00 in cash and 0.1457 shares of BioTelemetry stock or CHF8.00 in cash and 0.2185 shares of BioTelemetry stock. The deal is worth nearly CHF 260 million and will be funded through cash on hand, debt and equity. The companies expect the deal to close in the third quarter.

US Physical Therapy ($USPH) has been notified by the New York Stock Exchange that the company is currently out of compliance with the exchange’s listing requirements. The company has failed to file  its 2016 10-K in a timely fashion. US Physical Therapy stated that  it has been unable to file its annual report because it needs additional time to complete its review of the accounting treatment for redeemable non-controlling interests of its acquired partnerships.

Gilead Sciences ($GILD) announced that its  hepatitis C meds Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) have been approved by the FDA to be used in patients aged 12 to 17. The two drugs were previously approved for use in adults only.

Bellerophon Therapeutics ($BLPH) reported its new clinical data on INOpulse in patients with pulmonary arterial hypertension. The findings show significant increases in cardiovascular measures with exercise with a "trend toward improvement" when subjects were at rest.

 

VWR ($VWR) announced that it has acquired MESM Ltd., a provider of laboratory and medical equipment and ancillary supplies to clinical trials globally. VWR said that the acquisition will help the company in offering “end-to-end product and supply chain solutions." The financial terms and conditions of the deal have not been disclosed.

Kura Oncology ($KURA) announced that it has dosed its first patient in its Phase 1 clinical trial of KO-947, a selective small molecule inhibitor of extracellular-signal-regulated kinases 1 and 2 (ERK1/2). The Phase 1 trial of KO-947 is designed to determine the maximum tolerated dose in patients with locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological malignancies.

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
Aegis
Reiterates
Alder Biopharmaceuticals (ALDR)
Buy
$41.00
Low
Jefferies Group LLC
Downgrades
AstraZeneca plc (AZN)
Buy -> Hold

Low
HC Wainwright
Reiterates
Celsion (CLSN)
Buy
$1.50
Low
Rodman & Renshaw
Initiates
Celsion (CLSN)
Buy
$1.50
Low
HC Wainwright
Lowers Target
Dicerna Pharmaceuticals (DRNA)
Buy -> Buy
$8.00 -> $5.00
Low
Piper Jaffray Companies
Initiates
Gemphire Therapeutics (GEMP)
Overweight
$30.00
Low
Gabelli
Initiates
Incyte (INCY)
Buy

Low
Janney Montgomery Scott
Initiates
TESARO (TSRO)
Neutral

Low

Gainers (% price change) Last Trade Change Mkt Cap
Akorn, Inc. AKRX 29.77 +4.55 (18.04%) 3.90B
Depomed Inc DEPO 13.75 +1.76 (14.68%) 858.88M
Impax Laboratories Inc IPXL 13.75 +1.00 (7.84%) 1.03B
CARDIOME PHARMA CORP CRME 3.20 +0.20 (6.51%) 103.00M
Albany Molecular Research AMRI 14.34 +0.81 (5.99%) 615.77M
Losers (% price change)
NewLink Genetics Corp NLNK 16.19 -1.35 (-7.70%) 473.06M
Infinity Pharmaceuticals INFI 2.42 -0.15 (-5.84%) 112.01M
Nektar Therapeutics NKTR 20.11 -0.93 (-4.42%) 3.09B
AngioDynamics, Inc. ANGO 16.21 -0.68 (-4.03%) 599.05M
ImmunoGen, Inc. IMGN 3.12 -0.12 (-3.70%) 262.03M
Most Actives (dollar volume)
Akorn, Inc. AKRX 29.77 +4.55 (18.04%) 3.90B
Gilead Sciences, Inc. GILD 66.58 +0.10 (0.15%) 87.05B
Merck & Co., Inc. MRK 63.13 -0.11 (-0.17%) 172.43B
UnitedHealth Group Inc UNH 166.02 +0.62 (0.37%) 159.72B
Pfizer Inc. PFE 34.10 -0.01 (-0.03%) 202.59B